Introduction of Artificial Intelligence to Provide Opportunities to South & Central America Helicobacter
Pylori (H. pylori) Non-invasive Testing Market Players
The advancement in the field of computer technologies has led to the introduction of artificial intelligence technologies, which have been utilized to enhance the diagnosis and predict disease progression and treatment planning. Several studies have shown the capability of artificial intelligence in predicting H. pylori status for diagnosing gastritis. In 2019, Cancer Informatics and Inspirata entered into a technical partnership with DeePathology to grant joint customers the ability to utilize the DeePathology H. pylori decision support system, a screening tool, directly from Dynamyx, a digital pathology solution by Inspirata. The product can enhance reporting accuracy and safely accelerate the H. Pylori diagnostic process. Thus, the emergence of artificial intelligence will offer new opportunities for pharmaceutical companies, which is expected to provide growth opportunities to the helicobacter pylori (H. pylori) non-invasive testing market.
Market Overview
The number of cancer cases in Argentina is increasing at a steady rate. According to WHO, in 2020, ~130,878 new cases of cancer were diagnosed, of which 22,024 were breast cancer, while 15,605 were colorectal cancer and others. Further, ~70,000 deaths are caused by cancer per year, which is the third-highest cancer mortality rate in Latin America. Breast cancer is the most common type, with 73 cases per 100,000 women each year. Moreover, according to OECD, the healthcare expenditure in Argentina has increased. The surge is due to a growing need for health systems, infrastructure, human resources, diagnostics, treatment, and financing owing to the rising number of diseases and infections across the country. These factors are expected to provide significant growth opportunities to the (H. pylori) non-invasive testing market players during the forecast period.
The South & Central America helicobacter pylori (H. pylori) non-invasive testing market is segmented on test type, test method, end user, and country.
Based on test type, the South & Central America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into serology, stool antigen, and urea breathe. In 2022, the urea breath segment is expected to hold the largest share of the market. Based on test method, the South & Central America Helicobacter pylori (H. pylori) non-invasive testing market is bifurcated into laboratory based and point of care. The laboratory based segment is expected to hold a larger share of the market in 2022. Based on end user, the South & Central America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into hospitals, clinics, and diagnostic laboratories. The diagnostic laboratories segment is expected to hold the largest share of the market in 2022. Based on country, the South & Central America Helicobacter pylori (H. pylori) non-invasive testing market is segmented into Brazil, Argentina, and the Rest of South & Central America. Further, Brazil is expected to hold the largest share of the market in 2022. Abbott Laboratories; Bio-Rad Laboratories Inc.; CerTest Biotec; Coris BioConcept; DiaSorin S.p.A.; Meridian Bioscience Inc.; QuidelOrtho Corporation; Sekisui Diagnostics; Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd; and Thermo Fisher Scientific Inc. are the leading companies operating in the helicobacter pylori (H. pylori) non-invasive testing market in South & Central America.